{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:00:51Z","timestamp":1784869251922,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the therapeutic outcomes of radioactive iodine (RAI) therapy for pulmonary metastases from differentiated thyroid carcinoma (DTC) and identify clinical factors predictive of treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 186 patients with pulmonary metastases of DTC who underwent RAI at our institution between 2010 and 2024. The treatment response was assessed based on integrated radiological and biochemical criteria using CT, I-131 scintigraphy, and serum thyroglobulin levels. Patients were classified as disease control complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Clinical variables including age, sex, histological subtype, timing of pulmonary metastasis diagnosis, maximum lesion diameter, pulmonary RAI uptake score, initial administered activity, and history of adjuvant RAI therapy were evaluated. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall disease control rate (CR\u2009+\u2009PR\u2009+\u2009SD) was 23.1%. Younger age (&lt;\u200955 years) and synchronous detection of pulmonary metastases at the time of thyroid surgery were identified as independent predictors of a favorable treatment response (odds ratio\u2009=\u20093.77 and 2.65, respectively). A strong positive correlation was observed between the pulmonary RAI uptake score and the therapeutic outcome (Spearman\u2019s \u03c1\u2009=\u20090.683,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In contrast, the initially administered activity (100 vs.\u2009\u2265\u2009150 mCi) was not significantly associated with treatment efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Younger age and synchronous detection of pulmonary metastases were identified as independent predictors, whereas pulmonary RAI uptake was strongly correlated with favorable RAI responsiveness in patients with DTC. The identified predictors of disease control may assist in optimizing patient selection and counseling for RAI therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11604-026-01982-y","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:09:56Z","timestamp":1781150996000},"page":"1450-1458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive factors for therapeutic response to radioactive iodine therapy in pulmonary metastases from differentiated thyroid carcinoma"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4328-5662","authenticated-orcid":false,"given":"Ken","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiyuki","family":"Uchihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kazama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Ojiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"1982_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMp1604412","volume":"375","author":"S Vaccarella","year":"2016","unstructured":"Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 2016;375:614\u20137. https:\/\/doi.org\/10.1056\/NEJMp1604412.","journal-title":"N Engl J Med"},{"key":"1982_CR2","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/hed.25029","volume":"40","author":"A Sanabria","year":"2017","unstructured":"Sanabria A, Kowalski LP, Shah JP, Nixon IJ, Angelos P, Williams MD, et al. Growing incidence of thyroid carcinoma in recent years: factors underlying overdiagnosis. Head Neck. 2017;40:855\u201366. https:\/\/doi.org\/10.1002\/hed.25029.","journal-title":"Head Neck"},{"key":"1982_CR3","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/hed.26987","volume":"44","author":"HG Vuong","year":"2022","unstructured":"Vuong HG, Le MK, Hassell L, Kondo T, Kakudo K. The differences in distant metastatic patterns and their corresponding survival between thyroid cancer subtypes. Head Neck. 2022;44:926\u201332. https:\/\/doi.org\/10.1002\/hed.26987.","journal-title":"Head Neck"},{"key":"1982_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/thy.2022.0353","volume":"33","author":"A Wilhelm","year":"2022","unstructured":"Wilhelm A, Conroy PC, Calthorpe L, Shui AM, Kitahara CM, Roman SA, et al. Disease-specific survival trends for patients presenting with differentiated thyroid cancer and distant metastases in the United States, 1992\u20132018. Thyroid. 2022;33:63\u201373. https:\/\/doi.org\/10.1089\/thy.2022.0353.","journal-title":"Thyroid"},{"key":"1982_CR5","doi-asserted-by":"publisher","first-page":"923182","DOI":"10.3389\/fendo.2022.923182","volume":"13","author":"CJ Hsu","year":"2022","unstructured":"Hsu CJ, Lai KY, Lu YL, Wu MH, Liu FH, Lin SF. Outcomes of patients with metastatic differentiated thyroid cancer after excellent response to treatment. Front Endocrinol. 2022;13:923182. https:\/\/doi.org\/10.3389\/fendo.2022.923182.","journal-title":"Front Endocrinol"},{"key":"1982_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/cen.13489","volume":"88","author":"SY Sohn","year":"2017","unstructured":"Sohn SY, Kim HI, Kim YN, Kim TH, Kim SW, Chung JH. Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow-up. Clin Endocrinol (Oxf). 2017;88:318\u201326. https:\/\/doi.org\/10.1111\/cen.13489.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1982_CR7","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1089\/cbr.2008.0501","volume":"23","author":"TN Showalter","year":"2008","unstructured":"Showalter TN, Siegel BA, Moley JF, Baranski TJ, Grigsby PW. Prognostic factors in patients with well-differentiated thyroid cancer presenting with pulmonary metastasis. Cancer Biother Radiopharm. 2008;23:655\u20139. https:\/\/doi.org\/10.1089\/cbr.2008.0501.","journal-title":"Cancer Biother Radiopharm"},{"key":"1982_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","volume":"35","author":"MD Ringel","year":"2025","unstructured":"Ringel MD, Sosa JA, Baloch Z, Bischoff L, Bloom G, Brent GA, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid. 2025;35:841\u2013985. https:\/\/doi.org\/10.1177\/10507256251363120.","journal-title":"Thyroid"},{"key":"1982_CR9","doi-asserted-by":"publisher","first-page":"e6809","DOI":"10.1097\/MD.0000000000006809","volume":"96","author":"R Wang","year":"2017","unstructured":"Wang R, Zhang Y, Tan J, Zhang G, Zhang R, Zheng W, et al. Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: an 8-year retrospective study. Med (Baltim). 2017;96:e6809. https:\/\/doi.org\/10.1097\/MD.0000000000006809.","journal-title":"Med (Baltim)"},{"key":"1982_CR10","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.4158\/EP151139.OR","volume":"22","author":"P Chen","year":"2016","unstructured":"Chen P, Feng HJ, Ouyang W, Wu JQ, Wang J, Sun YG, et al. Risk factors for nonremission and progression-free survival after I-131 therapy in patients with lung metastasis from differentiated thyroid cancer: a single-institute, retrospective analysis in Southern China. Endocr Pract. 2016;22:1048\u201356. https:\/\/doi.org\/10.4158\/EP151139.OR.","journal-title":"Endocr Pract"},{"key":"1982_CR11","doi-asserted-by":"publisher","first-page":"107327482091466","DOI":"10.1177\/1073274820914661","volume":"27","author":"C Li","year":"2020","unstructured":"Li C, Wu Q, Sun S. Radioactive iodine therapy in patients with thyroid carcinoma with distant metastases: a SEER-based study. Cancer Control. 2020;27:1073274820914661. https:\/\/doi.org\/10.1177\/1073274820914661.","journal-title":"Cancer Control"},{"key":"1982_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s13139-017-0502-9","volume":"52","author":"JH Choi","year":"2017","unstructured":"Choi JH, Byun BH, Lim I, Moon H, Park J, Chang KJ, et al. The predictive values of lesion size, F-18 FDG avidity and I-131 avidity for the clinical outcome of I-131 treatment in patients with metastatic differentiated thyroid carcinoma only in the lung. Nucl Med Mol Imaging. 2017;52:135\u201343. https:\/\/doi.org\/10.1007\/s13139-017-0502-9.","journal-title":"Nucl Med Mol Imaging"},{"key":"1982_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13139-013-0239-z","volume":"48","author":"DH Kim","year":"2013","unstructured":"Kim DH, Jung JH, Son SH, Kim CY, Hong CM, Jeong SY, et al. Difference of clinical and radiological characteristics according to radioiodine avidity in pulmonary metastases of differentiated thyroid cancer. Nucl Med Mol Imaging. 2013;48:55\u201362. https:\/\/doi.org\/10.1007\/s13139-013-0239-z.","journal-title":"Nucl Med Mol Imaging"},{"key":"1982_CR14","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892\u20139. https:\/\/doi.org\/10.1210\/jc.2005-2838.","journal-title":"J Clin Endocrinol Metab"},{"key":"1982_CR15","doi-asserted-by":"publisher","first-page":"e3911","DOI":"10.1210\/clinem\/dgab436","volume":"106","author":"J Sim\u00f5es-Pereira","year":"2021","unstructured":"Sim\u00f5es-Pereira J, Mourinho N, Ferreira TC, Limbert E, Cavaco BM, Leite V. Avidity and outcomes of radioiodine therapy for distant metastasis of distinct types of differentiated thyroid cancer. J Clin Endocrinol Metab. 2021;106:e3911\u201322. https:\/\/doi.org\/10.1210\/clinem\/dgab436.","journal-title":"J Clin Endocrinol Metab"},{"key":"1982_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2967\/jnumed.110.081059","volume":"52","author":"T Higashi","year":"2011","unstructured":"Higashi T, Nishii R, Yamada S, Nakamoto Y, Ishizu K, Kawase S, et al. Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med. 2011;52:683\u20139. https:\/\/doi.org\/10.2967\/jnumed.110.081059.","journal-title":"J Nucl Med"},{"key":"1982_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3803\/enm.2019.34.3.215","volume":"34","author":"J Liu","year":"2019","unstructured":"Liu J, Liu Y, Lin Y, Liang J. Radioactive iodine-refractory differentiated thyroid cancer and redifferentiation therapy. Endocrinol Metab (Seoul). 2019;34:215\u201325. https:\/\/doi.org\/10.3803\/enm.2019.34.3.215.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"1982_CR18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","volume":"2","author":"M Schlumberger","year":"2014","unstructured":"Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2:356\u20138. https:\/\/doi.org\/10.1016\/S2213-8587(13)70215-8.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1982_CR19","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.7150\/thno.57689","volume":"11","author":"JM Oh","year":"2021","unstructured":"Oh JM, Ahn BC. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics. 2021;11:6251\u201377. https:\/\/doi.org\/10.7150\/thno.57689.","journal-title":"Theranostics"},{"key":"1982_CR20","doi-asserted-by":"publisher","first-page":"R113","DOI":"10.1530\/ERC-19-0491","volume":"27","author":"C Buffet","year":"2020","unstructured":"Buffet C, Wassermann J, Hecht F, Leenhardt L, Dupuy C, Groussin L, et al. Redifferentiation of radioiodine-refractory thyroid cancers. Endocr Relat Cancer. 2020;27:R113\u201332. https:\/\/doi.org\/10.1530\/ERC-19-0491.","journal-title":"Endocr Relat Cancer"},{"key":"1982_CR21","doi-asserted-by":"publisher","first-page":"T179","DOI":"10.1530\/ERC-21-0024","volume":"28","author":"L Lamartina","year":"2021","unstructured":"Lamartina L, Anizan N, Dupuy C, Leboulleux S, Schlumberger M. Redifferentiation-facilitated radioiodine therapy in thyroid cancer. Endocr Relat Cancer. 2021;28:T179\u201391. https:\/\/doi.org\/10.1530\/ERC-21-0024.","journal-title":"Endocr Relat Cancer"},{"key":"1982_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12020-023-03302-0","volume":"81","author":"AM Gonz\u00e1lez-Clavijo","year":"2023","unstructured":"Gonz\u00e1lez-Clavijo AM, Cuellar AA, Triana-Urrego J, Barrero JA, Fierro-Maya LF. Metastatic differentiated thyroid cancer: worst prognosis in patients with metachronous metastases. Endocrine. 2023;81:90\u20137. https:\/\/doi.org\/10.1007\/s12020-023-03302-0.","journal-title":"Endocrine"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-01982-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-026-01982-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-026-01982-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:08:46Z","timestamp":1784866126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-026-01982-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1982"],"URL":"https:\/\/doi.org\/10.1007\/s11604-026-01982-y","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Review Board of Jikei University (approval no. 37-091 [12728]), and the requirement for informed consent was waived.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}